LifeMD Q2 results show margin expansion and branded GLP-1 pivot progressing
Aug 5, 2026, 4:13 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The combination of margin expansion, a clear path to profitability in H2 2026, and a concrete growth catalyst (XYOSTED collaboration) could re-rate LFMD higher, especially if quarterly EBITDA shows sustained improvement and the XYOSTED collaboration progresses toward scalable revenue. The main downside risk remains the XYOSTED launch costs and execution risk in a competitive GLP-1 landscape.
AI summary
What happened, with direct paths to the underlying reporting
LifeMD posted Q2 2026 revenue of $47.3M within guidance and an adjusted EBITDA loss around $3.5M, improving ~21% sequentially. Gross margin rose to 89% as in-house pharmacy scales and shipping costs drop, with recurring rebills at ~84% of revenue. Guidance now points to profitability in H2 2026 and a year-end run rate near $250M, supported by the XYOSTED collaboration with Halozyme/Antares and broader growth channels.
Q2 2026 revenue is $47.3M within guidance; adjusted EBITDA loss about $3.5M, down 21% QoQ.
95% of new weight-management patients start branded GLP-1; shift from compounded GLP-1 largely complete.
Gross margin expands to 89% (+280 bps YoY) as in-house pharmacy scales and shipping costs fall.
Weight Management Program subscribers ~108k; total active subscribers ~356k, up 20% YoY.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
